Drug intelligence / Profile preview

SBX 2022

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBX 2022 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of blood cancer. It is designed to control and prevent the proliferation and metastasis of hematologic malignancies. The drug is derived from Stramsen Biotech's extensive database of over 8,000 medicinal plants, which the company leverages to develop natural therapeutic approaches. As of 2025, the company secured $25 million in Series B funding to advance its pipeline of 33 drug candidates, including SBX 2022. While the specific botanical source and molecular targets are proprietary, the candidate is positioned as a natural therapeutic for oncology.

Beyond the preview

Go deeper on SBX 2022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX 2022.

Explore the full profile